Shenyang Sunshine Pharmaceutical Co., LTD.

Pharma

Shenyang, China, China

A Chinese pharmaceutical company focused on drug development and manufacturing.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

11 drugs in development

Phase 32

Phase 29

Phase 11

By Therapeutic Area

top 4

Oncology

758%

Hematology

325%

Nephrology

18%

Metabolic & Endocrine

18%

R&D Momentum

54/100

Pipeline Velocity

30/100

Trial Completion Rate

83/100

Pipeline Concentration

42/100

Pipeline Freshness

68/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Key Events

Mar 31, 2026TrialSafety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion

Mar 12, 2026TrialThe Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Nov 1, 2025TrialA Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Oct 24, 2025TrialA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Aug 4, 2025TrialSafety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Jul 30, 2025TrialSSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Jul 30, 2025TrialA Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Jul 18, 2025TrialA Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

4 more events

Jul 1, 2025TrialPhase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Jun 20, 2025TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer

Jun 16, 2025TrialPhase I Study of HBT-708 for Patients With Advanced Solid Tumors

Jun 12, 2025TrialA Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

HQShenyang, China, China

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SSS06Phase 2

SSS17Phase 2

rhEPOPhase 2

Metabolic & Endocrine

Hyperuricemia

PEGylated recombinant candida urate oxidasePhase 1

Nephrology

Chronic Kidney Disease

rhEPOPhase 3

Oncology

Intestinal Cancer

SSGJ-706+AGPhase 2

SSGJ-706+Bevacizumab+XELOXPhase 2

SSGJ-706+TPPhase 2

SSGJ-706+XELOXPhase 2

Non-Small Cell Lung Cancer

PD-1/L1 inhibitor combined with chemotherapyPhase 3

PD-1 Inhibitor + ChemotherapyPhase 2

SSGJ-706Phase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)